Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19.
Impact in
- Neurology 104
In The Last Decade
doi.org/w3022381041 →Countries where authors are citing Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19.
This map shows the geographic impact of Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19.. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19. with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19. more than expected).
Fields of papers citing Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19.
This network shows the impact of Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19.. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19..
About Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19.
This paper, published in 2020, received 244 indexed citations . Written by Savino Sciascia, Franco Aprà, Simone Baldovino, Roberto Boero, Stefano Bonora, Andrea Calcagno, Irene Cecchi, Marcella Converso, Martina Cozzi and Paola Crosasso. It is primarily cited by scholars working on Infectious Diseases (197 citations), Neurology (104 citations), Molecular Biology (30 citations), Oncology (15 citations) and Hematology (10 citations). Published in Clinical and Experimental Rheumatology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
This paper is also available at doi.org/w3022381041.